Quality of Life-a Goal for Schizophrenia’s Therapy

MIHAIL CRISTIAN PÎRLOG¹, DRAGOS OVIDIU ALEXANDRU¹, RUXANDRA ELENA POPESCU², LILIANA BALCU², LIVIA MIHAELA STRUNOIU¹, LAVINIA CORINA DUICA³, MIRCEA MIHAI DUȚESCU²

¹University of Medicine and Pharmacy of Craiova, Faculty of Medicine, Craiova, Romania
²Chronic Hospital of Psychiatry, Dumbrăveni, Romania
³Lucian Blaga University Sibiu, Faculty of Medicine, Sibiu, Romania

ABSTRACT: Quality of Life (QOL) assessment represents a good instrument to monitor the evolution of schizophrenia and the treatment’s outcomes. The present study has evaluated the relationship between the level of the QOL and different socio-demographical and clinical factors. Lower QOL for schizophrenic persons was influenced by the severity of symptoms and cognitive deficits, while same low level of QOL could be considered an indicator for suicidal behavior. The correct therapeutically management of individuals with schizophrenia could lead to better outcomes in terms of life satisfaction of patients and response to the treatment’s strategies.

KEYWORDS: quality of life, schizophrenia, social adjustment, suicidal behavior

Introduction

According to World Health Organization (WHO), the concept of Quality of Life (QOL) was defined as “an individual’s perception of their position in life in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards and concerns” [1]. The measuring of QOL, as a subjective perspective of the patient about his/her state of well-being, was related to several goals for health-care professionals: to prioritise, screen and identify the patient’s problems, to facilitate communication between staff and beneficiaries and to identify their preferences related with the ways of treatment, to assess the clinical evolution and the response to therapeutically approach, to collect data for audit and health policies [2].

Within the mental health services, it was showed that the QOL evaluation is directed to several domains of life as physical and psychological health status, professional activities, leisure, living arrangements, and social skills [3], in order to offer a balanced mix between objective and subjective perspectives of the concept [4, 5]. Thus, QOL has become an important indicator for mental health professionals, offering not only an image of the outcomes of their interventions, but also orientating their routine practice [6].

In individual with schizophrenia, the QOL assessment represents a good instrument to monitor the evolution of the disorder and the treatment’s outcomes and it has received a greater attention especially after the appearance of the atypical antipsychotic drugs, but also a serious challenge since these persons have cognitive deficits and lack of insight of their suffering [7]. The way in which QOL is it influenced in schizophrenia it is still not well known, even were highlighted factors which are actioned in a negative way such as lack of social support [8], unmet needs [9], severity of the symptoms [10], and drug side effects [11]. Moreover, it was emphasized that QOL for people with schizophrenia is worse if it is compared not only with that of the general population, but also with that of people with other medical conditions, and it is worsened as long as the illness is longer, and individuals integrated in community support programs have a better QOL than those who are institutionalized [12].

In this context, the improvement of QOL have became a consolidated goal in mental health services, demanded not only by the clients and their families, but also by the professionals and the institutions. The evaluation of the relationship between the level of QOL and the different therapeutically approach remains a field in which every new data could contribute to the drawing of better ways for the management of these individuals.

Material and methods

Our research was conducted on a study sample consisted of 73 inpatients who has fulfilled the ICD-10 and DSM-IV-TR criteria for chronic paranoid schizophrenia diagnosis, monitored between January 1st, 2016-July 31st, 2016 in the wards of the Chronics Psychiatry
Hospital Dumbraveni, Vrancea County. All the subjects were voluntarily recruited, and they were included in the study after it was obtained their informed consent. The present research was approved by the Committee of Ethics of the University of Medicine and Pharmacy of Craiova.

Data obtained were represented by socially-demographical (age, gender, residence, educational, professional and marital status) and clinical (time distance from onset, number of admissions, type of antipsychotic and adjuvant medication, suicidal and risky behaviors) items, and also data resulted after the using of the following instruments:

- WHOQOL-BREF scale to measure the level of QOL [13];
- Positive and Negative Syndrome Scale (PANSS) to measure the severity of symptoms [14];
- MMSE (Mini Mental Examination) scale for evaluation of cognitive status [15];
- Global Assessment of Functioning Scale (GAFS) to measure the global functioning of the subjects [16].

The results were statistically analyzed using SPSS (SPSS Inc.) and MS Excel (Microsoft Inc.), using classical statistic indicators for descriptive statistics (mean±SD, median and quartiles), respectively Chi-square and Spearman tests to assay the association between categorical variables and Mann-Whitney test to compare quantitative data (p values <0.05 being statistically significant).

**Results**

The average age of the subjects from the study sample was of 47.58±12.61 years, with the following distribution according to their gender: 41 men (56.16%) and 32 women (43.84%), respectively their residence-56 subjects from rural area (76.71%) and 17 living in urban areas (23.29%).

Also, 18 (24.66%) of them were married, while 43 were unmarried (58.90%), respectively 12 divorced (16.44%).

None of them were professionally active, 8 (10.96%) being social assisted and 65 (89.04%) beneficiaries of medical pension, while the analysis of the level of education has showed that 5 (6.84%) did not follow any schololar program, 22 (30.14%) only primary school, another 22 (30.14%) gymnasium, respectively 24 (32.88%) have graduated high school.

The risky behaviors were met in 39 (53.42%) of them for smoking, respectively 31 (42.47%) for alcohol consumption, out of which 25 (34.25) were consuming in an abusive way.

The biggest duration of evolution was 8 years (mean of 5.97±1.64 years), with a maximum of 20 admissions to a psychiatric setting (average of 6.62±3.62 admissions), and for the majority of the subjects (61-83.56%) the illness has started in a reactive way.

The assessment of the symptom’s severity both at admission and at discharge was realized by using PANSS scale and it was showed that for the patients from our study sample, the period of hospitalization has lead to a decrease of the severity of schizophrenia’s symptoms. The same slight improvement was recorded by the cognitive status of the subjects, but the level of cognitive deficits, as it was evaluated by using MMSE scale it is an important one (Table 1, Fig. 1, Fig. 2).

Only four (5.48%) of our subjects were able to obtain a positive level of social adjustment at discharge.

**Table 1. PANSS and MMSE scores for the subjects of study sample**

| PANSS | PANSS admission | PANSS discharge | p Kruskal-Wallis |
|-------|----------------|----------------|-----------------|
| Min   | 59             | 47             | 0.176           |
| Q1    | 79             | 66.75          |                 |
| Mediana | 84           | 76.5           |                 |
| Q3    | 94.25          | 88             |                 |
| Max   | 115            | 113            |                 |

| MMSE | MMSE admission | MMSE discharge | p Kruskal-Wallis |
|------|----------------|----------------|-----------------|
| Min  | 7              | 8              | 0.176           |
| Q1   | 13             | 16             |                 |
| Mediana | 16        | 19             |                 |
| Q3   | 19             | 22             |                 |
| Max  | 25             | 28             |                 |

**Fig. 1. Comparison of the PANSS scores at admission and discharge for the subjects of study sample**
The WHOQOL-BREF it is an instrument designed to measure four important domains of living, in direct relationship with QOL [13]: D1-Physical health (activities of daily living, dependence on medicinal substances and medical aids, energy and fatigue, mobility, pain and discomfort, sleep and rest, work capacity); D2-Psychological (bodily image and appearance, negative feelings, positive feelings, self-esteem, spirituality/religion/personal beliefs, thinking, learning, memory and concentration); D3-Social relationships (personal relationships, social support, sexual activity); D4-Environment (financial resources, freedom, physical safety and security, health and social care: accessibility and quality, home environment, opportunities for acquiring new information and skills, participation in and opportunities for recreation/leisure activities, physical environment: pollution/noise/traffic/climate, transport).

The results obtained in our study showed an important deficit in QOL for some of the subjects, with minimal scores ranging between 16 (D3) and 31 (D4), while for some of them, the psychological and social relationships domains have reached the maximum score of 100 (Table 2, Fig. 3).

| WHOQOL-BREF | WHOQOL-BREF | WHOQOL-BREF | WHOQOL-BREF |
|-------------|-------------|-------------|-------------|
| D1          | D2          | D3          | D4          |
| Min         | 19.00       | 25.00       | 16.00       | 31.00       |
| Q1          | 50.00       | 67.50       | 44.00       | 63.00       |
| Median      | 63.00       | 75.00       | 50.00       | 69.00       |
| Q3          | 75.00       | 81.00       | 69.00       | 75.00       |
| Max         | 94.00       | 100.00      | 100.00      | 94.00       |

Suicidal behavior was present 11 subjects (15.07%) and during the period assessed, 93.15% (68 subjects) of them have received a typical antipsychotic (haloperidol or levomepromazine) as first intention pharmacological treatment, followed by therapy with second generation antipsychotics as following: amisulpride (40 subjects-54.79%), quetiapine (5 subjects-6.85%), risperidone (50 subjects-68.49%), ziprasidone (1 subject-1.37%). Also, 72 of them (98.63%) were treated with antiparkinsonian drugs in order to deal with extrapiramidal symptoms induced by antipsychotics drugs, while for all of them mood stabilizers (valproic acid or carbamazepine) and...
benzodiazepines (to control the associated anxiety and depressive symptoms) were used as adjuvant therapy. Analysis of the results has proved the existence of a statistically significant correlation between QOL domains and the positive levels of social adjustment, while the suicidal behavior has influenced in a significant way only D1 (physical health) and D4 (Environment) domains of the WHOQOL-BREF (Table 3).

Moreover, the level of social adjustment, mostly poor (94.52%) as it was expressed by using GAF scale, was proved to be in a significant influenced relationship not only with QOL, but also with symptom’s severity and the level of cognitive deficits (Table 4).

| Social adjustment | Poor | Positive | p Mann Witney |
|-------------------|------|----------|---------------|
| WHOQOL-BREF D1    | 60.72±12.73 | 70.57±10.34 | 0.047 |
| WHOQOL-BREF D2    | 71.73±12.93 | 85.86±10.06 | 0.009 |
| WHOQOL-BREF D3    | 55.60±11.68 | 67.86±12.15 | 0.038 |
| WHOQOL-BREF D4    | 69.35±11.26 | 82.29±11.07 | 0.022 |

We have also found out that the level of cognitive deficit it is directly correlated in a significant way (p Spearman <0.05) with the level of subjective perceived physical health of the subjects, while higher levels of the schizophrenia’s symptoms severity were reversely associated with the remaining three domains of the WHOQOL-BREF, both at the admission and discharge of the patients (Table 5, Fig. 4, Fig. 5).

| Variable 1 | Variable 2 | Spearman rho | p value |
|------------|------------|--------------|---------|
| WHOQOL-BREF D1 | MMSE score admission | 0.206 | 0.0396 |
| WHOQOL-BREF D2 | PANSS score admission | -0.283 | 0.0045 |
| WHOQOL-BREF D3 | PANSS score admission | -0.369 | 0.0002 |
| WHOQOL-BREF D4 | PANSS score admission | -0.232 | 0.0205 |
| WHOQOL-BREF D2 | PANSS score discharge | -0.347 | 0.0004 |
| WHOQOL-BREF D3 | PANSS score discharge | -0.371 | 0.0002 |
| WHOQOL-BREF D4 | PANSS score discharge | -0.255 | 0.0105 |

![Fig. 4. Corellation between MMSEE and WHOQOL-BREF D1 scores](10.12865/CHSJ.44.02.05)
QOL remains an important indicator for schizophrenia’s evolution during the hospitalization period, and that it is also directly connected to some other factors from the psycho-social spectrum who are influenced during the illness course, such as social adjustment or cognitive deficit.

The schizophrenia’s heterogenous profile [18] was once more confirmed by our results, where just few items could be considered relatively constant such as professional inactivity, because of huge disabling potential of the illness, respectively poor social adjustment.
due to influence of disorder on the social skills of the person with this diagnosis. The statistically significant correlations founded between QOL and severity of the symptoms, for both moment of assessment (admission and discharge) are consistently with some data from literature, and not with others. Thus, it was underlined, as in our study, that the presence of positive and negative psychotic symptoms is correlated with low level of QOL [19], and the higher severity of these symptoms, while associated with anxiety and depression, leads to a worse self-perceived QOL [10,20,21]. Some other studies have showed different conclusions, and according to them, schizophrenia’s QOL is correlated more with comorbid depression [22,23], in schizophrenic individuals, depression being considered the most important predictor of poor QOL [24]. Our study has indicated that, despite other data from literature [23,25], the severity of symptoms was negative correlated with D2 (psychological), D3 (social relationships), respectively D4 (perception of environment) domains of QOL.

Not only schizophrenia symptoms have contributed to a low level of perceived QOL for the subjects from our study sample, but also the neurocognitive deficits, especially for the D1 (physical health) domain, some other studies [26,27] have showed the same correlation, even if being offered a clear explanation of the reciprocally impact of these items. Regarding the relationship between QOL and antipsychotic therapy, we found no statistically significant differences, neither between the effect of each substance used in treatment on the PANSS scores, nor in the WHOQOL-BREF scores. These results can be considered surprising, if we take in account the fact that the subjects from our study sample were treated with antiparkinsonian drugs in order to control the extrapyramidal side effects, and some other studies [28,29,30] have found a negative influence of these phenomena on QOL.

The lower QOL of schizophrenic patients and the other socio-cultural factors determined by the evolution of the illness are considered important risk factors for predicting the suicidal behavior [31]. The presence of suicidal attempts in 15.07% of subjects and the statistically significant influence of this behavior on two domains of QOL, combined with the severity of the symptoms are roughly in line with data from their studies [32,33].

Conclusion
The QOL of individuals of schizophrenia is directly and significant connected with clinical and social factors. Lower QOL for schizophrenic persons could be considered an indicator for suicidal risk. Severity of symptoms and neurocognitive deficits are factors with significant influence on the QOL and the correct management of them could lead to better outcomes of the therapeutically approach in terms of life satisfaction of patients. Good QOL remains an important goal in the schizophrenia’s treatment.

References
1. WHOQOL Group. Development of the WHOQOL: Rationale and current status. Int J Mental Health, 1994, 23:24-56.
2. Higginson IJ, Carr AJ. Using quality of life measures in the clinical setting. BMJ, 2001, 322(7297):1297-1300.
3. VanNieuwenhuizen C, Schene AH, Boevink WA, Wolf JRLM. Measuring the quality of life of clients with severe mental illness: a review of instruments. Psychiatr Rehabil J, 2011, 4:33-42.
4. Barry MM, Zissi A. Quality of life as an outcome measure in evaluating mental health services: a review of the empirical evidence. Social Psychiatry and Psychiatric Epidemiology, 1997, 32:38-47.
5. Fakhoury WH, Priebe S. Subjective quality of life: its association with other constructs. International Review of Psychiatry, 2002, 14:219-224.
6. Gigantesco A, Giuliani M. Quality of life in mental health services with a focus on psychiatric rehabilitation practice. Ann Ist Super Sanità, 2011, 47(4):363-372.
7. Skantze K, Malm U, Dencker SJ, May PR, Corrigan P. Comparison of quality of life with standard of living in schizophrenic outpatients. Br J Psychiatry, 1992, 161:797-801.
8. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis, 2003, 191:287-294.
9. Becker T, Leese M, Krumm S, Ruggeri M, Vazquez-Barquero JL. Needs and quality of life among patients with schizophrenia in five European centres: what is the impact of global functioning scores. Soc Psychiatry Psychiatr Epidemiol, 2005, 40:628-634.
10. Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L. Schizophrenia and quality of life: how important are symptoms and functioning? International Journal of Mental Health Systems, 2010, 4:31
11. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res, 1997, 6:21-26.
12. Bobes J, Garcia-Portilla MP. Quality of life in schizophrenia. In: Katschnig H, Freeman H, Sartorius N (Eds): Quality of Life in Mental Disorders. John Wiley & Sons Ltd, 2005, Chichester UK, 153-168.
13. WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med, 1998, 28:551-558.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987, 13(2):261-276.

15. Folstein MF, Folstein SE, McHugh PR. Mini-mental status-A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 1975, 12(3):189-198.

16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition. American Psychiatric Publishing Inc, 1994, Arlington VA US, 273-316.

17. Davidson L, McGlashan TH. A five-year followup study of deficit and nondeficit schizophrenia. Schizophrenia Research, 1997, 49:253-260.

18. Joebe HT. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry, 2005, 50:892-900.

19. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull, 2007, 33:1225-1237.

20. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan EO. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand, 1996, 94:118-124.

21. Norman RM, Mailla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, Cheng S, Rickwood A. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand, 2000, 102:303-309.

22. Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, de Castella AR, Rolfe T, Davey P, Kulkarni J. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand, 2001, 103:387-392.

23. Narholm V, Bech B. Quality of life in schizophrenic patients: Association with depressive symptoms. Nord J Psychiatry, 2006, 60:32-37.

24. Mechanic D, McAlpine D, Rosenfield S, Davis D. Effects of illness attribution and depression on the quality of life among persons with serious mental illness. Soc Sci Med, 1994, 39:155-164.

25. Lehman AF, Burns BJ. Severe mental illness in the community. In: Spilker B (Eds): Quality of life and pharmacoeconomics in clinical trials - 2nd edition. Lippincott-Raven, 1996, New York, 919-924.

26. Addington J, Addington D. Neurocognitive and social functions of schizophrenia. Schizophrenia Bulletin, 1999, 25:173-182.

27. Buchanan RE, Breier A, Kirkpatrick B, Ball P, William T, Carpenter J. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. American Journal of Psychiatry, 1998, 155:751-760.

28. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: A naturalistic comparative study. J Clin Psychopharmacol, 2004, 24:582-591.

29. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan EO. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand, 1996, 94(2):118-124.

30. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res, 1999, 8:417-426.

31. Ran MS, Xiang MZ, Mao WJ, Hou ZJ, Tang MN, Chen EY, Chan CL, Yip PS, Conwell Y. Characteristics of suicide attempters and nonattempters with schizophrenia in a rural community. Suicide Life Threat Behav, 2005, 35(6):694-701.

32. Ponizovsky AM, Grinshpoon A, Levav I, Ritsner MS. Life satisfaction and suicidal attempts among persons with schizophrenia. Compr Psychiatry, 2003, 44:442-447.

33. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Socio-demographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patients. J Psychiatric Res, 2008, 42:495-502.